Opinion

Video

Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Panelists discuss whether the trial results support investigating cretostimogene with other checkpoint inhibitors and provide insights into notable ongoing trials exploring cretostimogene for intermediate- or high-risk NMIBC, such as BOND-003 and PIVOT-006.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following questions:

      • Do you think the results of this trial support the investigation of cretostimogene in combination with other checkpoint inhibitors?
      • Can you briefly discuss other notable trials that are investigating cretostimogene for intermediate- or high-risk NMIBC?

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
      TMT for bladder cancer: Balancing cost and quality of life
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
      Investigators compare trimodal therapy vs cystectomy in MIBC
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Investigators assess ctDNA’s role in NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Redefining treatment for LG-IR-NMIBC
      Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
      Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
      Related Content
      Data supports combination intravesical chemotherapy for high-risk NMIBC
      July 10th 2025

      Data supports combination intravesical chemotherapy for high-risk NMIBC

      Hannah Clarke
      “This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Human urinary system | Image Credit: © magicmine - stock.adobe.com
      July 8th 2025

      Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

      Benjamin P. Saylor Hannah Clarke
      Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      Regulatory recap: FDA approvals in urology from the first half of 2025
      July 4th 2025

      Regulatory recap: FDA approvals in urology from the first half of 2025

      Hannah Clarke
      Take a look through all the regulatory milestones in urology from the first half of the 2025.
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      July 4th 2025

      Top 10 Urology Times videos from the first half of 2025

      Urology Times staff
      Catch up on exclusive videos you may have missed from the first half of the year.
      © 2025 MJH Life Sciences

      All rights reserved.